Who
R. Don Elsey
Director
Company insider
Files Form 4 as: Director, Bullfrog AI Holdings; Director, Opgen; Director, Regenerx Biopharmaceuticals; CFO, Treasurer & Secretary, Lyra Therapeutics; CFO, Secretary and Treasurer, Senseonics Holdings; Sr. VP/Chief Financial Officer, Regado Biosciences; Chief Financial Officer, Emergent BioSolutions.
In numbers
- Trades disclosed
- 186
- Buys
- 1
- Sells
- 13
- Bought
- $3,435
- Sold
- $2.1M
- Companies
- 7
- Companies where not an officer
- 3
- First trade
- 20 Sep 2006
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | BFRG Bullfrog AI Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BFRG Bullfrog AI Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 25 Sep 2025filed 29 Sep 2025 | BFRG Bullfrog AI Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 22 Aug 2025filed 26 Aug 2025 | BFRG Bullfrog AI HoldingsBiotechnology | SEC FORM 4 Code A | —5,710 at $0.00 | filing |
| 22 Aug 2025filed 26 Aug 2025 | BFRG Bullfrog AI HoldingsBiotechnology | SEC FORM 4 Code A | —2,813 at $0.00 | filing |
| 26 Sep 2024filed 12 Feb 2025 | BFRG Bullfrog AI Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 7 Jun 2023filed 9 Jun 2023 | Opgen | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 16 Apr 2023filed 9 May 2023 | BFRG Bullfrog AI Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 16 Apr 2023filed 18 Apr 2023 | BFRG Bullfrog AI Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 9 Jun 2022filed 10 Jun 2022 | Opgen | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 17 May 2022filed 19 May 2022 | Regenerx Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —290,000 at $0.00 | filing |
| 2 Aug 2021filed 4 Aug 2021 | Regenerx Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —290,000 at $0.00 | filing |
| 9 Jun 2021filed 10 Jun 2021 | Opgen | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 8 Feb 2021filed 10 Feb 2021 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 30 Sep 2020filed 2 Oct 2020 | Opgenoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 10 Jun 2020filed 12 Jun 2020 | Regenerx Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 30 Apr 2020filed 1 May 2020 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —20,635 at $0.00 | filing |
| 15 May 2019filed 17 May 2019 | Regenerx Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 13 May 2019filed 15 May 2019 | Regenerx Biopharmaceuticalsoption or derivative | SEC FORM 4 Code P | $39.1M15,625 at $2,500.00 | filing |
| 13 May 2019filed 15 May 2019 | Regenerx Biopharmaceuticalsoption or derivative | SEC FORM 4 Code P | — | filing |
News
Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)EBS · tickerreport.com · 16 Oct 2026Critical Survey: Emergent Biosolutions (NYSE:EBS) & Viridian Therapeutics (NASDAQ:VRDN)EBS · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name R. Don Elsey; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.